Responses
Featured Posters: Poster Rounds with the Professors
AS16. Screening/Early detection
PR088/#198 EZH2/EZH1 inhibitor tulmimetostat (CPI-0209): preliminary phase II results and first biomarker findings in patients with arid1a-mutant ovarian clear cell or endometrial carcinomas (OCCC/EC)
Compose a Response to This Article
Other responses
No responses have been published for this article.